MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-22-2024
Karuna Therapeutics Retained Earnings 2011-2026 | KRTX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Karuna Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -998 M | -564 M | -288 M | -144 M | -75.5 M | -32.1 M | -14 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14 M | -998 M | -302 M |
Quarterly Retained Earnings Karuna Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -884 M | -765 M | -662 M | -564 M | -488 M | -411 M | -346 M | -288 M | -260 M | -209 M | -175 M | -144 M | -144 M | -144 M | -144 M | -75.5 M | -75.5 M | -75.5 M | -75.5 M | -31.6 M | -31.6 M | -31.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -31.6 M | -884 M | -274 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
-832 M | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Galera Therapeutics
GRTX
|
-307 M | - | -32.59 % | $ 7.61 M | USA |
 |
Pharming Group N.V.
PHAR
|
-257 M | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Kamada Ltd.
KMDA
|
-43.9 M | $ 8.5 | -1.39 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Benitec Biopharma
BNTC
|
-228 M | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Inventiva S.A.
IVA
|
-33.6 M | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Compugen Ltd.
CGEN
|
-453 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Tiziana Life Sciences PLC
TLSA
|
-84.6 M | $ 1.21 | -3.97 % | $ 71.5 M | Britain |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
-56.5 M | $ 2.28 | -0.44 % | $ 1.03 M | Israel |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
|
Foghorn Therapeutics
FHTX
|
-632 M | $ 5.0 | 2.25 % | $ 315 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
154 M | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
-1.24 B | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 3.34 | -4.02 % | $ 116 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
-430 M | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Cabaletta Bio
CABA
|
-233 M | $ 2.94 | -3.29 % | $ 3.43 M | USA |
 |
Iterum Therapeutics
ITRM
|
-486 M | $ 0.16 | -5.45 % | $ 3.15 M |  Irlanda |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |